Galenica

Pharma’s Biggest Losses: Once-Dropped Drugs Make Lucrative Comebacks
BioSpace
Wed, 05/10/23 - 10:18 am
Gilead Sciences
GSK
momelotinib
Roche
Eli Lilly
lebrikizumab
Merck
Zejula
Amgen
Galenica
Veltassa
Cubicin
Galenica to Buy Relypsa for $1.53 Billion
TheStreet.com
Thu, 07/21/16 - 09:05 am
Galenica
Relypsa
M&A
Veltassa